4.7 Article

Prevalence and Challenges of Liver Diseases in Patients With Chronic Hepatitis C Virus Infection

Journal

CLINICAL GASTROENTEROLOGY AND HEPATOLOGY
Volume 8, Issue 11, Pages 924-933

Publisher

ELSEVIER SCIENCE INC
DOI: 10.1016/j.cgh.2010.06.032

Keywords

Hepatitis C Virus; Burden of Disease; Hepatic Comorbidities; Prevalence

Funding

  1. Vertex Pharmaceuticals Incorporated
  2. Human Genome Science Merck Roche
  3. Schering Plough
  4. Vertex Pharmaceuticals
  5. Roche

Ask authors/readers for more resources

Hepatitis C virus (HCV) infections pose a growing challenge to health care systems Although chronic HCV infection begins as an asymptomatic condition with few short term effects, it can progress to cirrhosis, hepatic decompensation, hepatocellular carcinoma (HCC), and death The rate of new HCV infections is decreasing, yet the number of infected people with complications of the disease is increasing In the United States, people born between 1945 and 1964 (baby boomers) are developing more complications of infection Men and African Americans have a higher prevalence of HCV infection Progression of fibrosis can be accelerated by factors such as older age, duration of HCV infection, sex, and alcohol intake Furthermore, insulin resistance can cause hepatic steatosis and is associated with fibrosis progression and inflammation If more effective therapies are not adopted for HCV, more than 1 million patients could develop HCV related cirrhosis, hepatic decompensation, or HCC by 2020, which will impact the US health care system It is important to recognize the impact of HCV on liver disease progression and apply new therapeutic strategies

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available